H. pylori Infection Management

First-Line Treatment Regimens

The American Gastroenterological Association recommends bismuth quadruple therapy for 14 days as the first-line treatment for H. pylori infection, consisting of a proton pump inhibitor (PPI) twice daily, bismuth 300mg four times daily, metronidazole 500mg three times daily, and tetracycline 500mg four times daily 1, 2, 3
The standard dose of PPI is twice daily, with options including pantoprazole 40mg, lansoprazole 30mg, omeprazole 20mg, esomeprazole 20mg, dexlansoprazole 30mg, or rabeprazole 20mg 1, 2, 3
Bismuth subsalicylate 262mg or bismuth subcitrate 120mg can be used, with a dosing frequency of four times daily 1, 2, 4
Metronidazole 500mg can be given three to four times daily, with a total daily dose of 1.5-2g 1, 2
Tetracycline 500mg is given four times daily 1, 2

If clarithromycin-based therapy fails, bismuth quadruple therapy can be used as a second-line treatment 1, 2, 3
If bismuth quadruple therapy fails, levofloxacin triple therapy can be used, consisting of a PPI twice daily, amoxicillin 1000mg twice daily, and levofloxacin 500mg once daily or 250mg twice daily 1, 2, 3, 4

Rifabutin triple therapy can be used as a third-line treatment, consisting of a PPI twice daily, amoxicillin 1000mg twice daily, and rifabutin 150mg twice daily or 300mg once daily 1, 2, 3, 4
High-dose dual therapy can be used as a rescue option, consisting of amoxicillin 2-3 grams daily in 3-4 split doses and a PPI high-dose twice daily 1, 2, 4

PPI dosing should always be twice daily, taken 30 minutes before meals on an empty stomach, to maximize efficacy 1, 2, 5
Treatment duration should be 14 days, as this is superior to 7-10 day regimens and improves eradication rates by approximately 5% 4, 5
Antibiotic reuse rules should be followed, with clarithromycin and levofloxacin never being reused due to high resistance rates, and amoxicillin and tetracycline being reusable due to low resistance rates 4, 2, 3, 5

In patients with penicillin allergy, bismuth quadruple therapy is the first choice, as it contains tetracycline instead of amoxicillin 4, 5

Antibiotic susceptibility testing should be obtained before attempting further treatment, and molecular testing for clarithromycin and levofloxacin resistance can guide therapy selection earlier in the algorithm 1, 2, 3, 6

Eradication should be confirmed with a urea breath test or monoclonal stool antigen test at least 4 weeks after completing therapy and at least 2 weeks after stopping PPIs, as serology is not reliable for confirmation 5, 7, 8

The European Society of Gastrointestinal Endoscopy recommends that bismuth quadruple therapy achieves 80-90% eradication rates even in areas with high clarithromycin and metronidazole resistance, making it superior to traditional triple therapy in most clinical scenarios, with the key advantage being no bacterial resistance to bismuth and rare tetracycline resistance (<5%) 9

For patients with penicillin allergy, the European Society of Gastrointestinal Endoscopy suggests bismuth quadruple therapy as the first choice, as it contains tetracycline instead of amoxicillin, and consider penicillin allergy testing to delist the allergy and enable amoxicillin use 9
If penicillin allergy is confirmed and bismuth is unavailable, the American Gastroenterological Association recommends using PPI + clarithromycin + metronidazole for 14 days (only in areas with documented clarithromycin resistance <15%) 9, 10